Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex

J Biol Chem. 2011 Nov 25;286(47):41018-27. doi: 10.1074/jbc.M111.274720. Epub 2011 Sep 28.

Abstract

Most transcription of the MYC proto-oncogene initiates in the near upstream promoter, within which lies the nuclease hypersensitive element (NHE) III(1) region containing the CT-element. This dynamic stretch of DNA can form at least three different topologies: single-stranded DNA, double-stranded DNA, or higher order secondary structures that silence transcription. In the current report, we identify the ellipticine analog GQC-05 (NSC338258) as a high affinity, potent, and selective stabilizer of the MYC G-quadruplex (G4). In cells, GQC-05 induced cytotoxicity with corresponding decreased MYC mRNA and altered protein binding to the NHE III(1) region, in agreement with a G4 stabilizing compound. We further describe a unique feature of the Burkitt's lymphoma cell line CA46 that allowed us to clearly demonstrate the mechanism and location of action of GQC-05 within this region of DNA and through the G4. Most importantly, these data present, as far as we are aware, the most direct evidence of intracellular G4-mediated control of a particular promoter.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cell Line, Tumor
  • Down-Regulation / drug effects*
  • Down-Regulation / genetics
  • Ellipticines / chemistry
  • Ellipticines / pharmacology*
  • Ellipticines / therapeutic use
  • Exons / genetics
  • G-Quadruplexes / drug effects*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Intracellular Space / drug effects
  • Intracellular Space / metabolism
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / genetics
  • Lymphoma, Non-Hodgkin / pathology*
  • Models, Molecular
  • Molecular Conformation
  • Molecular Targeted Therapy
  • Promoter Regions, Genetic / drug effects
  • Promoter Regions, Genetic / genetics*
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins c-myc / genetics*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Reproducibility of Results

Substances

  • 9-(dimethylaminoethoxy)ellipticine
  • Antineoplastic Agents
  • Ellipticines
  • MAS1 protein, human
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins c-myc
  • RNA, Messenger